Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...
Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...
January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.
Medical Xpress on MSN13d
Research Pinpoints Weakness in Lung Cancer’s DefensesResearchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...
Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...
A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.
Corporate borrowers shrugged off fears over inflation and concerns over tariffs to print tight trades and pay for ...
GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. Hoos is leaving GSK after nine ...
Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback